These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 21821466)

  • 1. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worldwide emergence of extensively drug-resistant tuberculosis.
    Shah NS; Wright A; Bai GH; Barrera L; Boulahbal F; Martín-Casabona N; Drobniewski F; Gilpin C; Havelková M; Lepe R; Lumb R; Metchock B; Portaels F; Rodrigues MF; Rüsch-Gerdes S; Van Deun A; Vincent V; Laserson K; Wells C; Cegielski JP
    Emerg Infect Dis; 2007 Mar; 13(3):380-7. PubMed ID: 17552090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and opportunities in developing novel drugs for TB.
    Kaneko T; Cooper C; Mdluli K
    Future Med Chem; 2011 Sep; 3(11):1373-400. PubMed ID: 21879843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extensively drug-resistant tuberculosis: current challenges and threats.
    Jain A; Mondal R
    FEMS Immunol Med Microbiol; 2008 Jul; 53(2):145-50. PubMed ID: 18479439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in discovery of new drugs for tuberculosis therapy.
    Riccardi G; Pasca MR
    J Antibiot (Tokyo); 2014 Sep; 67(9):655-9. PubMed ID: 25095807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.
    Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP
    J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tuberculosis drug resistance patterns and trends in a tuberculosis referral hospital, 1997-2009.
    Liu CH; Li HM; Li L; Hu YL; Wang Q; Yang N; Wang S; Zhu B
    Epidemiol Infect; 2011 Dec; 139(12):1909-18. PubMed ID: 21272420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis.
    Bakal RL; Gattani SG
    Eur J Med Chem; 2012 Jan; 47(1):278-82. PubMed ID: 22088956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.
    Almeida Da Silva PE; Palomino JC
    J Antimicrob Chemother; 2011 Jul; 66(7):1417-30. PubMed ID: 21558086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensively drug-resistant tuberculosis: epidemiology and management challenges.
    Dheda K; Warren RM; Zumla A; Grobusch MP
    Infect Dis Clin North Am; 2010 Sep; 24(3):705-25. PubMed ID: 20674800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical testing of new drugs for tuberculosis: current challenges.
    Lenaerts AJ; Degroote MA; Orme IM
    Trends Microbiol; 2008 Feb; 16(2):48-54. PubMed ID: 18182291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterium tuberculosis: drug resistance and future perspectives.
    Riccardi G; Pasca MR; Buroni S
    Future Microbiol; 2009 Jun; 4(5):597-614. PubMed ID: 19492969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensively drug-resistant tuberculosis: new strains, new challenges.
    Banerjee R; Schecter GF; Flood J; Porco TC
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-resistant tuberculosis: past, present, future.
    Chiang CY; Centis R; Migliori GB
    Respirology; 2010 Apr; 15(3):413-32. PubMed ID: 20337989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
    Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
    J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
    Sharma A; Khuller GK; Sharma S
    Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.